FKBP4 is a malignant indicator in luminal A subtype of breast cancer

Hanchu Xiong1,2*, Zihan Chen3*, Wenwen Zheng2, Jing Sun2, Qingshuang Fu4, Rongyue Teng1, Jida Chen1, Shuduo Xie1, Linbo Wang1, Xiao-Fang Yu2, Jichun Zhou1

1. Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China. 2. Cancer Institute, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China. 3. Surgical Intensive Care Unit, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310016, China. 4. Rui An Hospital of Traditional Chinese Medicine, Wenzhou, 325200, China.

* These authors contributed equally

Corresponding authors: Xiao-Fang Yu, E-mail: xfyu1@zju.edu.cn; Jichun Zhou, E-mail: jichun-zhou@zju.edu.cn

Abstract

Purpose: FKBP4 is a member of the immunophilin protein family, which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking associated with HSP90. However, the relationship between abnormal expression of FKBP4 and clinical outcome in luminal A subtype breast cancer (LABC) patients remains to be elucidated.

Methods: Oncomine, bc-GenExMiner and HPA database were used for data mining and analyzing FKBP4 and its co-expressed genes. GEPIA database was used for screening co-expressed genes of FKBP4.

Results: For the first time, we found that higher FKBP4 expression correlated with LABC patients and worse survival. Moreover, the upregulated co-expressed genes of FKBP4 were assessed to be significantly correlated with worse survival in LABC, and might be involved in the biological role of FKBP4.

Conclusion: The expression status of FKBP4 is a significant prognostic indicator and a potential drug target for LABC.

Key words: FKBP4; luminal A subtype breast cancer; co-expressed genes; bioinformatics analysis

Introduction

Breast cancer (BC) is the most common noncutaneous cancer and the most frequent cause of death in worldwide women [1]. Widespread adoption of screening increases breast cancer incidence in given population and current prognostic and predictive biomarkers have markedly improved treatment options for patients. However, BC is a heterogeneous disease of multiple distinct subtypes that differ genetically, pathologically, and clinically [2], it’s still necessary to find more reliable markers to further improve therapeutic strategy for individual patients.

The FK506-binding protein 4 (FKBP4, also known as FKBP52) has been reported to possess multiple functions in various kinds of cancers based on its interaction with different cellular targets[3-6]. For example, in prostate cancer FKBP4 is found to enhance the transcriptional activity of androgen receptor signaling [3]. However, the relationship between abnormal expression of FKBP4 and clinical outcome in luminal A subtype breast cancer (LABC) patients remains unknown. For the first time, we investigated FKBP4 expression in LABC and its interaction with clinicopathological features including molecular subtypes and clinical outcomes by bioinformatics analysis.

In the present study, we used Oncomine, the Human Protein Atlas (HPA) database and breast cancer gene-expression miner (bc-GenExMiner)
database to identify the potential difference of FKBP4 expression between BC cancer tissues and adjacent normal samples, as well as the association between FKBP4 and clinical parameters. We further probed into genetic alterations and clinical outcomes of high and low level of FKBP4 expression in breast cancer patients. Lastly, preliminary explorations of the mechanisms of FKBP4 involving BC were carried out by identifying co-expressed genes with a series of online databases.

Methods

Data mining and analyzing

The online cancer microarray database, Oncomine (www.oncomine.org) [7] was used to assess the transcription levels of FKBP4 in breast cancer specimens compared with that in normal controls by Students’ t-test. The immunohistochemistry results of FKBP4 and six co-expressed genes in breast cancer were retrieved from the Human Protein Atlas database (www.proteinatlas.org) [8]. The expression and prognostic module of bc-GenExMiner v4.2 (bcgenex.centregauducheau.fr) [9] were used to evaluate the clinicopathological characteristics and prognostic merit of FKBP4 and six co-expressed genes in human breast cancer.

COSMIC and cBioPortal analysis for mutations

COSMIC database (www.sanger.ac.uk/cosmic/) [10] and cBioPortal database (www.cbioportal.org) [11] were utilized for assessment of FKBP4 mutations.

Screening co-expressed genes of FKBP4

Co-expressed genes of FKBP4 in breast cancer were collected from GEPIA (gepia.cancerpku.cn) for further evaluation [12].

Enrichment analysis and pathway annotation

Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of FKBP4 co-expressed genes were analyzed using The Database for Annotation, Visualization and Integrated Discovery v6.8 (david.ncifcrf.gov)[13]. The String database (www.string-db.org) was applied to construct the protein-protein interaction network for the co-expressed genes identification [14].

Results

Uregulated expression of FKBP4 in breast cancer patients

Based on the Oncomine database, we discovered that FKBP4 mRNA expression was significantly upregulated in cancerous samples compared with normal samples in more than nine types of cancer, including breast cancer, bladder cancer, colorectal cancer, gastric cancer, leukemia and so forth (Figure 1A). Meanwhile, the transcription level of FKBP4 in different types of BC were higher than normal tissues, including ductal breast carcinoma in situ (DBC in situ) with fold change=3.650, invasive lobular breast carcinoma (ILBC) with fold change=2.245, and invasive ductal breast carcinoma (IDBC) with fold change=2.657, invasive ductal and invasive lobular breast carcinoma (IBC) with fold change=2.480 (Figure 1B-1E). To investigate the protein expression level of FKBP4 in BC, we assessed BC tissue samples and matched adjacent normal tissues from the HPA database. The HPA database indicated that FKBP4 expression was significantly elevated in cancerous tissues compared with corresponding normal tissues when using either antibody HPA006148 (Figure 2A-2D) or antibody CAB017441 (Figure 2E-2F).

Relationship of FKBP4 with the clinicopathological characteristics and the prognostic merit

In bc-GenExMiner database, for the molecular subtype, upregulated FKBP4 was significantly related to luminal A, luminal B and basal-like subtype patients than the normal group rather than HER2 positive subtype (Figure 3A). ER and PR status were both positively correlated with FKBP4 expression (Figure 3B-3C). In BC patients with HER2 overexpression, FKBP4 expression has no significant change compared with HER2 negative groups (Figure 3D). To further probe into the correlation of FKBP4 expression and survival, BC patients with diverse molecular subtypes were also investigated. Upregulated FKBP4 was only significantly related to worse survival in luminal A subtype patients (HR=1.38; 95%CI:1.12-1.70, p=0.0027), but not correlated to those in luminal B, HER2 positive and basal-like subtypes of breast cancer patients (HR=0.97; 95%CI:0.75-1.26, p=0.8098; HR=1.08; 95% CI:0.81-1.44, p=0.5835; HR=0.83; 95% CI:0.64-1.07, p=0.1539) (Figure 3E–3H). Taken together, we found that upregulated FKBP4 expression was correlated with poor survival in LABC patients.

The impact of alterations in FKBP4 gene on the clinical survival

By using Catalogue of Somatic Mutations in Cancer (COSMIC), the pie chart described the mutations information including missense substitution, synonymous substitution and frameshift insertion. Missense substitution rate was 67.50%, synonymous substitution rate was 25.83% and...
nonsense substitution rate was 1.67% of mutant samples of BC. BC mainly had 34.21% G>A, 28.95% C>T and 11.40% G>T mutation in FKBP4 coding strand (Figure 4A-4B). Alteration frequency of FKBP4 mutation in BC was analyzed by using cBioPortal. From 0.25% to 4.25% mutation in the patients with BC was observed (Figure 4C). After analyzed by Kaplan-Meier plot and log-rank test, the alterations in FKBP4 were found no correlations with overall survival (OS) (p=0.507) or disease-free survival (DFS) (p=0.919) in BC patients with/without FKBP4 alterations (Figure 4D–4E).

Figure 1. FKBP4 mRNA expression in malignant tumors (Oncomine database). (A) The graph is a representation of the datasets with statistically significant mRNA overexpression (red) or reduced expression (blue) of FKBP4 gene (cancer vs normal). Cell color was determined by the best gene rank percentile for the analyses within the cell, and the gene rank was analyzed by percentile of target gene in the top of all genes measured in each research. (B) Comparison of FKBP4 mRNA expression between normal breast tissue and DBC. (C) Comparison between normal breast tissue and ILBC. (D) Comparison between normal breast tissue and IDBC. (E) Comparison between normal breast tissue and IBC. *P<0.05, **P<0.01, ***P<0.001.

Figure 2. Immunohistochemical staining of FKBP4 protein in BC (HPA database). Representative images of immunohistochemical staining of FKBP4 expression in BC samples and matched adjacent normal tissues.
Figure 3. Relationship of FKBP4 with the clinicopathological characteristics and the prognostic merit (bc-GenExMiner v4.2 database). The relationship between mRNA expression of FKBP4 and (A) different molecular subtypes, (B) ER, (C) PR, (D) HER2. Survival curves are plotted for patients of (E) luminal A, (F) luminal B, (G) HER2-positive, (H) basal-like.

Figure 4. FKBP4 genes expression and mutation analysis in BC (COSMIC and cBioPortal). (A, B) Pie-chart showed the percentage of the mutation type of FKBP4 in BC according to COSMIC database. (C) Oncoprint in cBioPortal represented the proportion and distribution of samples with alterations in FKBP4 gene. (D) Kaplan-Meier plots comparing OS in cases with/without FKBP4 gene alterations. (E) Kaplan-Meier plots comparing disease free survival (DFS) in cases with/without FKBP4 gene alterations.
Bioinformatics analysis of FKBP4 co-expressed genes

A total number of 200 FKBP4 co-expression genes collected from GEPIA were analyzed using the Database for Annotation, Visualization and Integrated Discovery v6.8 (DAVID). The Gene Ontology enrichment analysis comprised three categories: a biological process (BP), a molecular function (MF), and a cellular component (CC). The most valuable 10 pathways of each category were presented in Figure 5A-5C, suggesting that FKBP4 co-expression genes might participate in multiple basic functions including protein folding and binding. The protein-protein interaction (PPI) network was displayed using the String database (Figure 6), and three pairs of co-expressed genes with the highest combined scores (TCP1, CCT2, CCT6A, CCT7, STIP1 and HSP90AB1) were collected from PPI network (Table 1).
Expression and correlation of co-expressed genes with clinical survival in breast cancer patients

Based on the Oncomine database, we found that mRNA expressions of TCP1, CCT2, CCT6A, CCT7, STIP1 and HSP90AB1 were significantly upregulated in cancerous samples compared with normal samples in various types of cancer, including BC (Figure 7A-7F). The HPA database indicated that there were high levels of the above-mentioned six co-expressed genes in breast cancer tissues: TCP1 (Antibody CAB017460), CCT2 (Antibody HPA003198), CCT6A (Antibody HPA045576), CCT7 (Antibody HPA008425), STIP1 (Antibody CAB017448), and HSP90AB1 (Antibody CAB005230) (Figure 8A-8F).

Moreover, correlations between co-expressed genes and clinical survival were analyzed by using bc-GenExMiner v4.2, and the Kaplan-Meier curve showed that increased levels of co-expressed genes were all significantly correlated with worse survival in both overall BC (Figure 9A-9F) and LABC (Figure 10A-10F). Meanwhile, six co-expressed genes had no connection with worse survival in luminal B, HER2 positive and basal-like subtypes of BC (Figure 11A-11R). Taken together, upregulated FKBP4 co-expressed genes expression were all correlated with poor survival in LABC patients.

Discussion

Breast cancer is a leading cause of cancer-related deaths in women aged 40 years and younger[1]. Although in recent years early detection and personalized therapeutics have decreased mortality of BC, discovering novel prognostic indicators are still necessary for improving the prognosis of BC patients. Here, we found that upregulated FKBP4 might play a central role in regulating its co-expressed protein expression in BC.

FK506-binding protein (FKBP) family in Homo sapiens (human) genomes has included 18 FKBP5 up to date, which can target on various pathways in embryonic development, stress response, cardiac function, cancer tumorigenesis and neuronal function [15]. In breast cancer, FKBP5 is the most extensively
studied protein among identified human FKBPs, which is demonstrated to interact with HSP90 to affect steroid hormone receptor function [16]. In colorectal cancer, silencing FKBP3 has been found to attenuate oxaliplatin resistance by regulation of the PTEN/AKT axis [17].

A growing body of studies observed that FKBP4 expression was also upregulated in different types of cancers, e.g., head and neck cancer, prostate cancer, glioblastoma, ovarian cancer, colon cancer, and so forth [3, 6, 18-22]. Particularly, data from Yang’s study showed that FKBP4 was significantly upregulated in majority of BC cell lines [5], but its expression status and prognostic merit in LABC still remains unclear. In light of these previous studies, we conducted this research to assess the clinical and molecular regulatory importance of FKBP4 in LABC.

Figure 7. The mRNA expression of FKBP4 co-expressed genes in malignant tumors (Oncomine database). The graph is a representation of the datasets with statistically significant mRNA overexpression (red) or reduced expression (blue) of TCP1, CCT2, CCT6A, CCT7, STIP1 and HSP90AB1 gene (cancer vs normal). Cell color was determined by the best gene rank percentile for the analyses within the cell, and the gene rank was analyzed by percentile of target gene in the top of all genes measured in each research.

Figure 8. The protein level of FKBP4 co-expressed genes in BC tissues (HPA database). (A) TCP1 (Antibody CAB017460) expression in BC tissues. (B) CCT2 (Antibody HPA003198) expression in BC tissues. (C) CCT6A (Antibody HPA045576) expression in BC tissues. (D) CCT7 (Antibody HPA008425) expression in BC tissues. (E) STIP1 (Antibody CAB017448) expression in BC tissues. (F) HSP90AB1 (Antibody CAB005230) expression in BC tissues.
Figure 9. Survival curves in BC patients are plotted for overall subtypes correlated with (A) TCP1, (B) CCT2, (C) CCT6A, (D) CCT7, (E) STIP1, (F) HSP90AB1.

Figure 10. Survival curves in BC patients are plotted for luminal A subtype correlated with (A) TCP1, (B) CCT2, (C) CCT6A, (D) CCT7, (E) STIP1, (F) HSP90AB1.
In Oncomine and IHC analysis, we illustrated that both mRNA and protein expression of FKBP4 were significantly upregulated in BC tissues than corresponding normal tissues. Then, we detected that FKBP4 high expression in BC significantly correlated with positive nodal status ($p=0.0165$), ER ($p<0.0001$) and PR ($p=0.0004$) status. As for the molecular subtype, the highest expression of FKBP4 was found in luminal B subtype but irrelevant to HER-positive subtype, which suggested FKBP4 might play an indispensable role in ER and PR signaling pathway.

We then used bc-GenExMiner v4.2 database to elucidate that upregulated mRNA expression of FKBP4 was associated with unfavorable survival for all BC patients, and only correlated to worse survival in LABC patients when considering different receptor subtypes. Since ER and PR played pivotal roles in the development and progression of LABC [23], meanwhile FKBP4 chaperonin HSP90 promoted tumor progression by enhancing various oncogenes [24], more researches are warranted to find out whether FKBP4 influences the ER or PR status via HSP90 or they perform collectively toward the prognosis in the BC setting.

Genetic polymorphisms impose vital impact on malignant tumors, but neither Hogewind’s research [25] nor current study revealed that FKBP4 polymorphisms was correlated with breast cancer risk, therefore further researches should be carried out to figure out the prognostic role of FKBP4 polymorphisms in BC patients.

Among the co-expressed genes of FKBP4, a total of six co-expressed genes, TCP1, CCT2, CCT6A, CCT7, STIP1 and HSP90AB1, were finally focused. TCP1, CCT2, CCT6A, CCT7 are all belong to the chaperonin containing TCP1 complex (CCT) [26] and STIP1 is an adaptor protein that coordinates the functions of HSP90AB1 [27]. CCT family members overexpression have been reported involved in gene expression and regulation of various carcinomas [28-32]. STIP1 and HSP90AB1 are found associated with cell metastasis, apoptosis and other oncogenic functions in human cancer cells [33]. In our study, higher expressions of six co-expressed genes were all significantly increased in LABC compared to adjacent healthy controls. Moreover, they were all correlated with a shorter survival time in LABC patients. Therefore, we speculate that these co-expressed genes might also similarly interact with each other via various signaling pathways in LABC. The mechanisms and functions between FKBP4 and co-expressed genes remain elusive and need to be validated, thus promoting the development of efficient therapeutic strategies in LABC in the future.

Acknowledgments

We thank all authors for their critical reading and informative advice during the revision process. We apologize to all researchers whose relevant contributions were not cited due to space limitations.
Author Contributions
Writing—Original Draft Preparation, X.H.C. and C.Z.H.; Writing—Review & Editing, Z.W.W., S.J., F.Q.S., T.R.Y., C.J.D., X.S.D., W.L.B. and Y.X.F.; Funding Acquisition & Supervision, Z.J.C.. All authors have reviewed the manuscript.

Funding
The work was supported by the National Natural Science Foundation of China (No. 81972453, No. 81972597, No. 81602471 and No. 81672729), Zhejiang Provincial Natural Science Foundation of China under Grants (No. LY19H160055, LY19H160059, LY18H160005, LY20H160026). The work was sponsored by Zheng Shu Medical Elite Scholarship Fund.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Nagini S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-cancer agents in medicinal chemistry. 2017; 17: 152-63.
2. Sachs N, de Ligt J, Kopper O, Gologa E, Bounova G, Wexler F, et al. A Living Biobank of Breast Cancer Organioids Causes Disease Heterogeneity. Cell. 2018; 172: 373-86.e10.
3. Fedderer-Gaponder JR, Quintavalle C, Muller DC, Dietsche T, Perrina V, Lorber T, et al. Delineation of human prostate cancer evolution identifies chromothripsis as a polycovial event and FKBP4 as a potential driver of castration resistance. The Journal of pathology. 2018; 245: 74-84.
4. Kiyamova R, Garifulin O, Gryshkova V, Costianes I, Shayian M, Gout I, et al. Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2012; 17: 362-71.
5. Yang WS, Moon HG, Kim HS, Choi EJ, Yu MH, Noh DY, et al. Proteomic approach reveals FKBP4 and S10A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer. Journal of proteome research. 2012; 11: 1078-88.
6. Mohanta S, Sekhar Khora S, Suresh A. Cancer Stem Cell based molecular predictors of tumor recurrence in Oral squamous cell carcinoma. Archives of oral biology. 2019; 99: 92-106.
7. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY). 2004; 6: 1-6.
8. Uhlen M, Bjorling E, Agaton C, Szpyrkov V, Kostianets O, Shyian M, Gout I, et al. Human protein atlas for normal and cancer tissues based on antibody proteomics. Molecular & cellular proteomics : MCP. 2005; 4: 1920-32.
9. Jezquel P, Campone M, Gouraud W, Goutin-Charbonnel C, Leux C, Ricolleau G, et al. bc GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast cancer research and treatment. 2012; 131: 765-75.
10. Forbes SA, Beare D, Gunasekaran P, Leung K, Biridal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43: D865-11.
11. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2: 404-14.
12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research. 2015; 43: W98-w102.
13. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 47-51.
14. Sekulaczyn D, Galah AL, Lyon DJ, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic acids research. 2019; 47: D607-d13.
15. Chartney-Kwansah G, Li Z, Feng R, Wang L, Zhou X, Chen FZ, et al. Comparative analysis of FRKB family protein: evaluation, structure, and function in mammals and Drosophila melanogaster. BMC Dev Biol. 2018; 18: 7.
16. Dhamad AE, Zhou Z, Zhou J, Du Y. Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ERalpha) and Biochemical Characterization of the ERalpha-Hsp70 Interaction. PLoS ONE. 2016; 11: e0151637.
17. Tong J, Shen Y, Chen X, Wang R, Hu Y, Zhang X, et al. FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression. Oncology reports. 2019.
18. M. Litzburger UM, Müller A, Nagel K, Bach KJ, Borse L, Ochs K, Sahn F, et al. Suppression of DKO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. Glia. 2015; 63: 78-90.
19. Bhawal A, Majumder S, Ghosh S, Basu S, Sen D, Roychowdhury S, et al. Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression. Scientific reports. 2017; 7: 9763.
20. Braat M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, et al. Association of promoter methylation of VGF and PGR9.5 with ovarian cancer progression. PLoS One. 2013; 8: e70878.
21. Garifulin OM, Kykot VO, Gridina NY, Kiyamova RG, Gout I, Ilonenko VV. Application of serex-analysis for identification of human colon cancer antigens. Experimental cancer research. 2015; 37: 173-80.
22. Matsumoto H, Yamamoto Y, Shima M, Kuruma H, Berald J, Matsuya H, et al. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. Cancer Res. 2013; 73: 5206-17.
23. Wang M, Chen H, Wu K, Ding A, Zhang M, Zhang P. Evaluation of the prognostic stage in the 8th edition of the American Joint Committee on Cancer in locally advanced breast cancer: An analysis based on SEER 18 database. Breast (Edinburgh, Scotland). 2018; 37: 56-63.
24. Simpson NE, Lambert WM, Watkins R, Glashuiddin S, Huang SJ, Oxlmark E, et al. High levels of Hsp90 chaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res. 2010; 70: 8446-56.
25. Hopwood BF, Micheal S, Bakker B, Hong CB, den Hollander AI. Analysis of single nucleotide polymorphisms in the SFRS3 and FKBP4 genes in corticosteroid-induced ocular hypertension. Ophthalmic genetics. 2012; 33: 221-4.
26. Spiess C, Meyer AS, Reismann S, Frydman J. Mechanism of the eukaryotic chaperonin: protein folding in the chamber of secrets. Trends in cell biology. 2004; 14: 598-604.
27. Song Y, Masson DC. Independent regulation of Hsp70 and Hsp90 chaperones by Hsp70/Hsp90-organizing protein Sti1 (Hsp70). The Journal of biological chemistry. 2005; 280: 31878-85.
28. Guest ST, Kratche ZR, Bollig-Fischer A, Haddad R, Ethier SP. Two members of the TRiC chaperonin complex, CCT2 and TCPI are essential for survival of breast cancer cells and are linked to driving oncogenes. Experimental cell research. 2015; 332: 223-35.
29. Zou Q, Yang ZL, Yuan Y, Li JH, Liang LF, Zeng GX, et al. Clinicopathological features and CCT2 and PDI/A2 expression in gyllbladder squamous/adenosquamous carcinoma and gyllbladder adenocarcinoma. World journal of surgical oncology. 2013; 11: 143.
30. Carr AC, Khaled AS, Bassioni R, Flores O, Nierenberg D, Bhatti H, et al. Targeting chaperonin containing TCP1 (CCT) as a molecular therapeutic for small cell lung cancer. Oncotarget. 2017; 8: 110273-88.
31. Ying Z, Tian H, Li R, Lian J, Liu W, Wu S, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-β signaling. The Journal of clinical investigation. 2017; 127: 1725-40.
32. Nibbe RK, Markowitz S, Myeroff L, Ewing R, Ethier SP. Two members of the TRiC chaperonin complex, CCT2 and TCPI are essential for survival of breast cancer cells and are linked to driving oncogenes. Experimental cell research. 2015; 332: 223-35.
33. Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, et al. Stress-induced phosphoprotein 1 mediates head and neck carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018; 37: 3514-27.